Pharmafile
Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?
Autumn 2019
Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.
Contacts
Capabilities
Suggested News & Insights
Growth Meets Guardrails: Getting You Ready for the New Realm of Ad/PromoWednesday, May 13, 2026U.S. FDA Issues First Drug Supply Chain Security Act Warning Letter Targeting a Dispenser, Signaling Expanded Enforcement FocusApril 15, 2026Sidley Represents AIP in Its US$1.272 Billion Acquisition of Avanos MedicalApril 14, 2026Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from TakedaApril 3, 2026FDA's Crackdown On Drug Ads Conflicts With PrecedentApril 2, 2026Sidley Recognized in Legal 500 EMEA 2026March 25, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory